Browse
Submit Data
Databases
API
Help

Dataset Information

14 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Randomized phase II study with UFT capsule /LV or UFT E-granule /LV adjuvant chemotherapy for patients with completely resected high-risk stage II and III colorectal cancer

ABSTRACT: Interventions: UFT capsule / LV for 28 days with 7 days rest for 180days (6months)(1 course=5weeks, 35days). UFT E-granule / LV for 28 days with 7 days rest for 180days (6months)(1 course=5weeks, 35days). Primary outcome(s): treatment complete rate Study Design: Parallel Randomized

DISEASE(S): Colorecrtal Cancer

PROVIDER: 2626356 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A Randomized Trial of Adjuvant Chemotherapy with UFT / LV versus PSK / UFT / LV following curative resection for Stage II / III Colorectal Cancer

Project description:Interventions: Group A (standard therapy group:UFT/LV 6M): Administration of 5 courses (6 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. Group B (trial therapy group: PSK/UFT/LV 6M): Administration of 5 courses (6 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. And administration of every day PSK (3g/body) for 6 months. Group C (trial therapy group: PSK/UFT/LV 12M): Administration of 10 courses (12 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. And administration of every day PSK (3g/body) for 12 months. Primary outcome(s): 3 year desease free survival rate Study Design: Parallel Randomized

| 2620921 | ecrin-mdr-crc

Phase III Comparative Clinical Trial of Treatment Schedules for Oral UFT/LV Therapy as Postoperative Adjuvant Chemotherapy for Stage IIB/III Colorectal Cancer

Project description:Interventions: Group A (standard therapy group): Administration of 5 courses (6 months) of a schedule (consecutive administration method) in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. Group B (trial therapy group): Administration of 15 courses (18 months) of a schedule (5 days on, 2 days off: Saturday and Sunday) in which one course consists of 5 weeks of UFT (300 mg/m2/day) and LV (75 mg/day) for 5 consecutive days followed by 2 days off. Primary outcome(s): disease-free survival Study Design: Parallel Randomized

| 2609649 | ecrin-mdr-crc

Clinical trial on the efficacy of the UFT/LV for the Stage II colorectal cancer with risk factors for recurrence

Project description:Interventions: UFT/LV as postoperative adjuvant chemotherapy for the stage II colorectal cancer is tested as follows: one patient group for 28 days with 7 days rest (everyday medication) and another patient group for 5days with 2days rest (5-days on/2-days, Saturday and Sunday, off). Both medications are conducted for 25weeks as 5 courses (1 course=5weeks, 35days) from the date of the start of the therapy. After the treatment, both patient groups are simply observed without any more therapy, unless any recurrent lesions or any other cancer lesions are observed in them. The surgery alone group is simply observed without therapy, unless any recurrent lesions or any other cancer lesions (synchronous cancers or multiple colorectal cancers) are observed in them. Primary outcome(s): Disease-free survival Study Design: Parallel Randomized

| 2623196 | ecrin-mdr-crc

Phase II study of first line chemotherapy with UFT/LV in elderly patients with advanced/recurrent colorectal cancer.

Project description:Interventions: UFT 300mg/m2/day and LV 75mg/body/day is administered orally for 28 days every 35 days. Primary outcome(s): response rate Study Design: Single arm Non-randomized

| 2622557 | ecrin-mdr-crc

Clinical trial on the QOL of the Tegafur/Uracil plus Leucovolin(UFT/LV) to adjuvant chemotherapy for the Stage II, III colorectal cancer

Project description:Interventions: Tegafur/uracil with oral leucovorin(UFT/LV) UFT is administered orally at 300mg/m2/day with 75mg/day of oral leucovorin for 21 consecutive days followed by a 7 days rest. Primary outcome(s): Quality of Life Study Design: Single arm Non-randomized

| 2624363 | ecrin-mdr-crc

A feasibility study of adjuvant therapy with UFT/LV plus oxaliplatin following curative resection for stage III colorectal cancer

Project description:Interventions: UFT 300mg per m2 per day and LV 75mg per day for 28 days Oxaliplatin:85mg/m2 day1,15 every 5-weeks for 3-cycle After this therapy, followed by UFT/LV until 1 year Primary outcome(s): Patients ratio with completion of adjuvant TEGAFOX therapy Study Design: Single arm Non-randomized

| 2618840 | ecrin-mdr-crc

Phase II study of chemotherapy with UFT/LV/Bevacizumab in elderly patients with advanced and recurrent colorectal cancer.

Project description:Interventions: UFT 300mg/m2/day and LV 50mg/body/day is administered orally for 21 days every 28 days. Bevacizumab 5mg/kg is administered intravenous injection on day 1,15. Primary outcome(s): Overall response rate Study Design: Single arm Non-randomized

| 2618906 | ecrin-mdr-crc

A randomized phase II trial of adjuvant chemotherapy with UFT/LV versus S-1 following curative resection for stage III colorectal cancer

Project description:Interventions: UFT 300mg per m2 per day and LV 75mg per day for 28 days every 5-weeks for 6 months TS-1 80mg per m2 per day for 28 days every 6-weeks for 12 months Primary outcome(s): 3-year disease free survival rate Study Design: Parallel Randomized

| 2617052 | ecrin-mdr-crc

Switch maintenance using UFT/LV therapy after Oxaliplatin based adjuvant chemotherapy for StageIV colorectal cancer

Project description:Interventions: Within 8 weeks after Oxaliplatin based chemotherapy (UFT/LV Switch maintenance:5 course) UFT/LV p.o:4weeks on 1week off to be repeated every 5weeks Primary outcome(s): The complete of treatment,Safety Study Design: Single arm Non-randomized

| 2624724 | ecrin-mdr-crc

Switch maintenance using UFT/LV therapy after Oxaliplatin based adjuvant chemotherapy for StageIII colorectal cancer

Project description:Interventions: Within 8 weeks after Oxaliplatin based chemotherapy (UFT/LV switch maintenance:5 course) UFT/LV p.o(4 weeks on,1week off ) to be repeated every 5 weeks. Primary outcome(s): The complete rate of treatment, Safety Study Design: Single arm Non-randomized

| 2624723 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data